Argos Therapeutics (ARGS) Misses Q3 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 inches lower as Middle East tensions outweigh tech gains
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Argos Therapeutics Reports Fourth Quarter and Year-End 2014 Financial Results
March 30, 2015 4:05 PM EDT- Full Enrollment and Randomization in the Pivotal Phase 3 ADAPT Trial of AGS-003 for Metastatic Renal Cell Carcinoma (mRCC) Expected by the end of 2nd Quarter -
- First Interim Analysis from the ADAPT Trial by IDMC Expected in the 2nd Quarter -
- Conference Call and Webcast Today, March 30th, at 4:30 p.m. ET -
DURHAM, N.C., March 30, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq: ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies... More
